Ricerc@Sapienza

Background and aim: Although hypertension guidelines highlight the benefits of achieving the recommended blood pressure (BP) targets, hypertension control rate is still insufficient, mostly in high or very high cardiovascular (CV) risk patients. Thus, we aimed to estimate BP control in a cohort of patients at high CV risk in both primary and secondary prevention.

Introduction: Despite hypertension guidelines suggest that the most effective treatment strategy to improve blood pressure (BP) target achievement is to implement the use of combination treatment, monotherapy is still widely used in the clinical practice of hypertension.
Aim: To investigate BP control under monotherapy in the setting of real-life.

Hypertension continues to be the most common preventable cardiovascular risk factor in Europe. Blood pressure (BP) control in the continent remains largely unsatisfactory. For this reason, development of new guidelines has appeared timely and appropriate. In this article, we highlight the novel or controversial aspects of 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines and discuss how they will influence physicians’ management of hypertension in Europe.

This is a review article aiming to make focus on the changes made in the most recent sets of clinical recommendations and indications from European Society of Cardiology (ESC)/European Society of Hypertension (ESH) guidelines for the management of arterial hypertension. In particular, in this article we attempted to focus on the main new elements introduced in order to meet the need of doctors to adhere to guidelines and to provide their patients with the most updated recommendations for the clinical management of hypertension.